Weight‑loss drugs raise hair‑loss risk for genetically predisposed men, study finds

Men who are already genetically predisposed to androgenetic alopecia—the most common form of hair loss—face an additional 7 percent risk of experiencing hair loss when they take glucagon‑like peptide‑1 (GLP‑1) receptor agonists such as semaglutide (Ozempic), tirzepatide (Zepbound) or the higher‑dose formulation of semaglutide marketed as Wegovy for type 2 diabetes and obesity. The finding comes from a recent observational study that compared the incidence of hair‑loss diagnoses among men with a known genetic risk profile who were prescribed these medications to a matched control group not using GLP‑1 therapies.

Researchers analyzed health records and genetic data to isolate the effect of the drugs, controlling for age, body‑mass index and comorbid conditions. While the absolute increase in risk is modest, the study highlights a potential side effect of widely prescribed GLP‑1 agonists that clinicians may need to discuss with patients who are concerned about hair loss. Further investigation is warranted to confirm the association and to understand the underlying mechanisms.